Company: SNY
Filing Date: 2025-10-29
Form Type: 424B5
Source: 0001193125-25-255563
Chunk: 11

Company: Sanofi
Filing Date: 2025-10-29
Form: 424B5
Chunk 11
---
 a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline.
Furthermore, Blueprint’s established presence among allergists, dermatologists, and immunologists is expected to improve Sanofi’s ability to enhance its growing immunology pipeline. The acquisition also includes elenestinib, a
next-generation medicine for SM, as well as BLU-808, a highly potent and selective oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. Under the terms of the
acquisition, Sanofi paid $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion for 100% of the shares. Blueprint shareholders also received one non-tradeable and
non-transferable contractual contingent value right (“CVR”) per share which entitles the holders thereof to receive two potential milestone payments of $2.00 and $4.00 per CVR on the attainment of
future development and regulatory milestones within the applicable milestone period, respectively, for BLU-808. The total equity value of the transaction, including potential CVR payments, represented
approximately $9.5 billion on a fully diluted basis.

On July 22, 2025, Sanofi announced that it had entered into an agreement
to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, United Kingdom. The acquisition brings to Sanofi an early-stage combination vaccine candidate for respiratory syncytial virus and human
metapneumovirus, both respiratory viruses, and is expected to expand Sanofi’s capabilities in vaccine design and development with Vicebio’s “Molecular Clamp” technology. Under the terms of the agreement, Sanofi would acquire
all of Vicebio’s share capital for a total upfront payment of $1.15 billion, with potential milestone payments of up to $450 million based on development and regulatory achievements. The transaction is expected to close in the fourth
quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals

On August 6, 2025, Sanofi
acquired all outstanding common shares of Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $8 per share in cash at
closing. Based on $8.00 per